Physician profile
Cory Higley
NPI 1629500053
$2,199.14
in general payments reported to CMS, 2019-2025
23 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.83 · 2021: $148 · 2022: $293 · 2023: $175 · 2024: $633 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $340.28 | 2022-2025 | |
| Boston Scientific Corporation | $266.55 | 2021-2024 | Resolution 360 Clip, Captivator II, Exalt Model D |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.51 | 2022-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $169.34 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $138.90 | 2019-2025 | |
| Erbe USA INC | $120.00 | 2023-2024 | Erbe Apc3 |
| Intercept Pharmaceuticals, INC. | $111.99 | 2022 | |
| Janssen Biotech, INC. | $103.24 | 2024-2025 | Tremfya |
| Qol Medical, LLC | $98.84 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $93.82 | 2024-2025 | Eohilia, Entyvio |
| Ferring Pharmaceuticals INC. | $91.75 | 2024-2025 | Rebyota |
| Genzyme Corporation | $84.34 | 2025 | |
| Pfizer INC. | $64.82 | 2025 | |
| Lilly USA, LLC | $59.98 | 2024-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $41.70 | 2024 | Dificid, Zerbaxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $34.72 | 2025 | Vegzelma |
| Medtronic, INC. | $29.19 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $27.36 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $26.15 | 2025 | Rezdiffra |
| Ardelyx, INC. | $24.61 | 2025 | Ibsrela |
| Novo Nordisk INC | $20.58 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $18.03 | 2025 | Vowst |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Higley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.